wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38404422-01C7957E-BE02-48F7-89AA-51DFA99D1F2E
Q38404422-01C7957E-BE02-48F7-89AA-51DFA99D1F2E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-01C7957E-BE02-48F7-89AA-51DFA99D1F2E
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
P2860
Q38404422-01C7957E-BE02-48F7-89AA-51DFA99D1F2E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-01C7957E-BE02-48F7-89AA-51DFA99D1F2E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
38c4135fe57d9f81540a31d707b3606ba694db31
P2860
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.